quinoxalin-4-ylthio)acetic acid hydrazide (10) was used as a precursor for the syntheses of novel quinoxaline derivatives with potential anticonvulsant properties. The newly synthesized compounds have been characterized by IR, 1 H NMR, and mass spectral data followed by elemental analysis. The anticonvulsant evaluation was carried out for eleven of the synthesized compounds using metrazol induced convulsions model and phenobarbitone sodium as a standard. Among this set of tested compounds, two of them (14, and 15b) showed the best anticonvulsant activities.
Introduction
Syntheses of quinoxalines have attracted a great deal of attention in view of their potent biological and pharmacological activities including anticonvulsant [1] [2] [3] [4] , antibacterial [5] , antifungal [6] , antiviral [7] , antitubercular [8] , antileishmanial [9] , antiamoebic [10] , analgesic [11] , antihistaminic [12] , antineoplastic [13] , hypoglycemic [14] , MAO-A inhibitor [15] , antiarrhythmic [16] , antiatherosclerotic [17] , antiobese [18] , and other diverse pharmacological activities.
Earlier studies revealed that most of compounds derived from 1,2,4-triazoles have been found to be significant anticonvulsant [19] and tranquillizing agents [20] .
Furthermore, compounds 1a-e in Figure 1 which contain [1, 2, 4] triazolo [4,3-a] quinoxaline moiety showed promising anticonvulsant activity [21] .
We describe the synthesis and biological evaluation of novel [1, 2, 4] triazolo [4,3-a] quinoxaline derivatives expected to have anticonvulsant activity starting from 1,2-diaminobenzene and oxalic acid via quinoxaline ring build-up.
Results and Discussion

Chemistry.
The [1, 2, 4] triazolo [4,3-a] quinoxaline derivatives were prepared using established methodology as shown in Scheme 1. 2,3-Dichloroquinoxaline (3) was prepared by chlorination of 2,3-dihydroxyquinoxaline (2), which in turn was prepared by the condensation of the commercially available 1,2-diaminobenzene with oxalic acid in aqueous hydrochloric acid. Treatment of 3 with hydrazine hydrate yielded the corresponding 3-hydrazino compound, 4, which was subjected to ring closure to 5 by treatment with triethyl orthoformate. Reaction of 5 with thiourea in absolute ethanol afforded the isothiouronium intermediate which upon basic hydrolysis yielded [1, 2, 4] triazolo [4,3-a] quinoxaline-4-thiol (6) . The potassium salt 7 was obtained after treatment of 6 with alcoholic KOH in a quantitative yield.
Reaction of the potassium salt 7 with substituted aniline in DMF gave the corresponding anilide 8a-d, and its reaction with alkyl chloroacetate in the same solvent gave the corresponding ester 9a-e. The hydrazide derivative 10
1a-e R = H, CH 3 , CF 3 , substituted phenyl R 1 = substituted phenyl Figure 1 was synthesized from the reaction of n-butyl ester with hydrazine hydrate. 
Biological Activity
3.1. Anticonvulsant Activity. Eleven compounds of the newly synthesized derivatives were selected to be screened for their anticonvulsant activity on different groups of mice. Swiss albino adult male mice, weighing 20-25 g, were used as experimental animals. They were obtained from an animal facility (Animal House, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University). Mice were housed in stainless steel wire-floored cages without any stressful stimuli. Animals were kept under well-ventilated conditions at room temperature (25) (26) (27) (28) (29) (30) ∘ C). They were fed on an adequate standard laboratory chow (El-Nasr Co., AbouZabal, Egypt) and allowed to acclimatize with free access to food and water for 24-hour period before testing except during the short time they were removed from the cages for testing. Albino mice were randomly arranged in groups, each of six animals. Phenobarbitone sodium was used as a reference drug for comparison. Pentylenetetrazole (PTZ, Sigma Chemicals, USA) was used as convulsant.
The tested compounds were dissolved in DMSO and orally administered in a dose regimen ranging from 200 to 800 mg/kg animal weight, using the dosing volume of 0.2 mL per 20 g. Pentylenetetrazole was dissolved in normal saline in 2% concentration and was given intraperitoneally in a dose of 60 mg/kg body weight (dose that could induce convulsions in at least 80% of the animals without death during the following 24 hours). Phenobarbitone sodium (Alex Co., Egypt) was dissolved in normal saline in 2% concentration and it was intraperitoneally given in doses of 6.25, 12.5, and 25 mg/kg using the same dosing volume. All drugs were freshly prepared to the desired concentration just before use.
Groups of six mice were administered the graded doses of the test compounds and phenobarbitone sodium orally. Control animals received an equal volume of saline (10 mL/kg). After one hour, the animals were subcutaneously injected with the convulsive dose of pentylenetetrazole (60 mg/kg). The criterion of anticonvulsant activity is complete protection against convulsions of any kind. Observations were made at least 60 minutes after the administration of pentylenetetrazole. Doses that gave full protection against the induced convulsions and those which exhibited 50% protection in addition to the relative potencies of the test compounds to phenobarbitone sodium were recorded in Table 1 . Observations were made at least 60 min after the administration of metrazol.
Experimental
4.1.
General. Melting points were determined by open capillary and are uncorrected. The IR spectra (in KBr discs) were recorded on potassium bromide discs on a Pye Unicam SP 3300 spectrophotometer.
1 H NMR spectra were recorded either on Gemini 300 MHz (Varian USA) or on Jeol ECA 500 MHz NMR spectrometer (500 MHz) using TMS as an internal standard. All chemical shifts are reported in ppm downfield from TMS. Mass spectra were recorded on a Shimadzu GCMS-QP 1000 EX mass spectrometer operating at 70 eV. Elemental analysis was carried out at the Regional Center for Mycology and Biotechnology, Al-Azhar University, Cairo, Egypt. Progress of the reactions was monitored by TLC sheets precoated with UV fluorescent silica gel Merck 60 F254 plates and was visualized using UV lamp and n-hexane : ethyl acetate 9 : 1 as mobile phase. Starting materials were purchased from Aldrich Chemical Company and used without further purification. Compounds 2-6 were prepared following the procedures reported in the literature [22] [23] [24] . The used intermediates (chloroacetanilides and alkyl chloroacetates) were prepared as reported [25, 26] . 
Preparation of Potassium
SOCl 2 DMF NH 2 NH 2 ·H 2 O NH 2 NH 2 NH 2 ·H 2 O O O O O O O O O O SH O O NHNH 2 HC-(OEt) 3 (2) NaOH Alcoholic KOH 8a-d 8a R = H 8b R = COOH 8c R = OH 8d R = NO 2 R R 9a-e 17a-f 9a R = methyl 9b R = ethyl 9c R = n-propyl 9d R = n-butyl 9e R = tert-butyl = Ph = 4-CH 3 Ph = 2-OHPh = 4-OHPh = 4-ClPh = 2, 4-DiClPh Ar-CHO Glacial AcOH 16 CS 2 KOH R R -NCS 15aR = Et 15bR = Ph (1)
Preparation of 2-([1,2,4]Triazolo[4,3-a]quinoxalin-4-ylthio)-N-(substituted phenyl)acetamide (8a-d).
General procedure: a mixture of compound 7 (1.0 g, 0.01 mol) and the appropriate chloroacetanilide (0.01 mol) in DMF (20 mL) was heated over a water bath for 3 h. The reaction mixture was then cooled, poured into ice-cooled water (200 mL), and stirred well for 30 min. The solid thus separated was filtered, washed with water, dried, and crystallized from methanol/toluene mixture (1 : 1) to obtain compounds 8a-d. 
Preparation of Alkyl-2-([1,2,4]triazolo[4,3-a]quinoxalin-4-ylthio)acetate
Preparation of 2-([1,2,4]Triazolo[4,3-a]quinoxalin-4-ylthio)acetic Acid Hydrazide (10).
Compound 9b (3.3 g, 0.01 mol) was dissolved in absolute ethanol (50 mL) and treated with hydrazine hydrate (95%, 20 mL). The reaction mixture was stirred well and heated to 50 ∘ C for two hours, then cooled and treated with water (200 mL). The solid thus obtained was filtered, washed with water, dried, and then crystallized from glacial acetic acid to give 2.85 g (91%), m. 
Preparation of 1-[2-([1,2,4]Triazolo[4,3-a]quinoxalin-4-ylthio)]acetyl-3,5-dimethylpyrazole (11).
A mixture of 10 (1 g, 0.0028 mol) and acetylacetone (0.36 g, 0.0028 mol) in absolute ethanol (20 mL) was heated at 80 ∘ C on a water bath for 7 h. The reaction mixture was cooled and poured onto water, and the formed precipitate was filtered and crystallized from ethanol to give 0.78 g (64%), m. 
Preparation of 1-[2-([1,2,4]Triazolo[4,3-a]quinoxalin-4-ylthio)acetyl]-4,5-dihydro-5-methylpyrazol-5-one (12).
A mixture of 10 (1 g, 0.0028 mol) and ethyl acetoacetate (0.47 g, 0.0028 mol) in dioxane (20 mL) was heated under reflux for 
Preparation of 5-{([1,2,4]Triazolo[4,3-a]quinoxalin-4-ylthio)methyl}-1,3,4-oxadiazole-2-thiol (13).
A mixture of 10 (1 g, 0.01 mol), KOH (0.01 mol), and CS 2 (20 mL) in DMF (20 mL) was heated under reflux until the H 2 S ceased to evolve (about 5 h). The excess solvent was removed by distillation, the residue was stirred with water and filtered, and the filtrate was acidified with 10% HCl. The precipitated solid was filtered, washed with water, and crystallized from ethanol to give 0.9 g (86%), m.p. > 360 ∘ C, IR (KBr) cm (15a, b) . A mixture of compound 10 (1 g, 0.006 mol) and the appropriate thiocyanate (0.006 mol) in 20 mL absolute ethanol was heated under reflux for 3 h. After cooling, the precipitate was collected and crystallized from dioxane to obtain compounds (15a-b). 
Preparation of 1-([1,2,4]Triazolo[4,3-a]quinoxalin-4-ylthio)acetyl-4-cyclohexylsemicarbazide (14).
Preparation of N-Arylidene Derivative of 2-([1,2,4]
Triazolo [4,3-a] quinoxalin-4-ylthio)acetic Acid Hydrazide (17a-f). General procedure: a mixture of 1.0 g (0.028 mol) of compound 10 and the appropriate aromatic aldehyde (0.029 mol) in absolute ethanol (20 mL) and catalytic amount of glacial acetic acid (2 mL) was refluxed for 3-4 h, and the reaction mixture was then poured onto water. The solid so obtained was filtered and crystallized from acetic acid to obtain compounds 17a-f. 
Conclusion
In the present investigation, 16 new 4-substituted [1, 2, 4] triazolo [4,3-a] quinoxaline derivatives were synthesized and characterized by spectral analysis. Few of those derivatives were screened for anticonvulsant activity by PTZ animal model. Compounds 14 and 15b exhibited the highest activity which is comparable to the standard. The activity may be explained by the presence of substituents on position 4 of the condensed heterocyclic system containing quinoxaline, fused to triazole at 1,2 positions in the backbone structure of title compounds. The electronic factors exerted by the substituents and the hydrophobic nature of phenyl nucleus in the title compounds influenced the activity.
